REC8 and acute myeloid leukemia: We also identified some mutation-associated epigenetically dysregulated genes, including REC8 and HOXA7. Together, these epigenetic signatures represent potential therapeutic targets regardless of the different types of the underlying mutations present in individual AML cases.